This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (18)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Neuro-otology  • Balance Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

George A. Gates, MD; J. Douglas Green, Jr, MD; Debara L. Tucci, MD; Steven A. Telian, MD

Arch Otolaryngol Head Neck Surg. 2004;130:718-725.

Objective  To evaluate the efficacy of a portable low-intensity alternating pressure generator, the Meniett device, in controlling the symptoms of Ménière's disease.

Design  A randomized, placebo-controlled, double-blind, multicenter clinical trial of 4 months' duration.

Setting  Four study sites: 3 academic medical centers and 1 private practice.

Patients  Sixty-seven people aged 33 to 71 years with established, active, unilateral cochleovestibular Ménière's disease randomly assigned to a treatment or control group. Five cases were excluded (2 dropouts, 3 protocol violations), leaving 62 evaluable cases.

Intervention  The Meniett device was self-administered 3 times daily. The placebo Meniett device was identical but exerted no pressure. All participants had a tympanostomy tube inserted in the affected ear.

Main Outcome Measures  Participants rated vertigo and activity each day on a symptom report card. Hearing tests, electrocochleography, and questionnaires were completed at baseline, 2 months, and 4 months.

Results  The treatment group experienced significantly less severe vertigo, fewer days with definitive vertigo, and fewer days lost from work (sick days) during the follow-up period than did the control group. Hearing and electrocochleographic results did not differ between the groups. Outcomes did not differ by age, gender, laterality, or duration of symptoms. Outcomes were affected by vestibular loss and baseline level of vertigo. The tympanostomy tube had no short-term effect on vertigo symptoms. There were no complications from using the Meniett device.

Conclusion  The Meniett device is a minimally invasive, safe, and efficacious intermediate treatment for people with substantial vertigo uncontrolled by medical therapy.

From the Department of Otolaryngology–Head and Neck Surgery, University of Washington School of Medicine, Seattle (Dr Gates); Jacksonville Hearing and Balance Institute, Jacksonville, Fla (Dr Green); Division of Otolaryngology–Head and Neck Surgery, Duke University, Durham, NC (Dr Tucci); and Department of Otolaryngology–Head and Neck Surgery, University of Michigan Medical Center, Ann Arbor (Dr Telian). Dr Gates served as a paid consultant to Medtronic Xomed at a scientific retreat in 2002.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Meniett Clinical Trial: Long-term Follow-up
Gates et al.
Arch Otolaryngol Head Neck Surg 2006;132:1311-1316.
ABSTRACT | FULL TEXT  

Validation of the Meniere's Disease Patient-Oriented Symptom-Severity Index
Gates and Verrall
Arch Otolaryngol Head Neck Surg 2005;131:863-867.
ABSTRACT | FULL TEXT